Ausgabe 5/1998
Inhalt (15 Artikel)
Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions
Jeffrey A. Johnson, Erwin Friesen
The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
Alain Desgagné, Anne-Marie Castilloux, Jean-François Angers, Jacques Le Lorier
Should Antibacterials Be Deregulated?
Joan Rovira, Montserrat Figueras, Josep L. Segú
Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients
George Dranitsaris, Peter Phillips, Coleman Rotstein, Anitasha Puodziunas, Steve Shafran, Gary Garber, Fiona Smaill, Irving Salit, Mark Miller, Kurt Williams, John Conly, Joel Singer, Steve Ioannou
Predicting Hospitalisation of Patients with Diabetes Mellitus
Samir K. Bhattacharyya
Linking the Health Utilities Index to National Medical Expenditure Survey Data
John A. Rizzo, Steven Pashko, Rebecca Friedkin, John Mullahy, Jody L. Sindelar
How to Calculate Indirect Costs in Economic Evaluations
Werner B. F. Brouwer, Marc A. Koopmanschap
Cost Analysis of the Treatment of Schizophrenia in the UK
Stephen Almond, Owen O’ Donnell
Assessing the Willingness of Parents to Pay for Reducing Postoperative Emesis in Children
Lara Diez
The Economic Cost of Multiple Sclerosis in Sweden in 1994
Freddie Henriksson, Bengt Jönsson
Economic Evaluation of Multiple Sclerosis in the UK, Germany and France
Nuala Murphy, C. Confavreux, J. Haas, N. König, E. Roullet, M. Sailer, M. Swash, C. Young, J. -L. Mérot
Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease
Pedro Plans-Rubió
Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox
Kenneth J. Smith, Mark S. Roberts